Abstract
Background A hybrid Failure Mode Effect Analysis (FMEA) based on fuzzy logic and multicriteria decision analytics was applied as a post-marketing surveillance tool for troubleshooting potential quality problems of Artemisinin Combination Therapies (ACTs) as a means of aggregating subjective opinions of quality experts in providing vital information for continuous management and improvement of safety and quality standards.
Research design and methods An FMEA team of five cross-functional quality experts implemented a hybrid fuzzy FMEA model based on Analytical Hierarchy Process (AHP) and Technique for Order of Preference by Similarity to Ideal Solution (TOPSIS) to solve multicriteria decision problems in quality risk analysis of historic quality control data of ACTs.
Results Expert opinions were captured as triangular fuzzy numbers to represent the linguistic scoring of risk-determining variables for fifteen failure modes. The fuzzy AHP enabled systematic ranking of the variables, while the fuzzy TOPSIS algorithm provided easily understood and configurable computational procedures for ranking the failure modes based on optimal geometric paths to positive and negative ideal solutions.
Conclusions The quality risk of ACTs could be reliably established using the fuzzy FMEA where aggregated experts’ decisions and risk variables’ weights are of considerable importance to the final ranking of quality failures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Research Fund of the Tertiary Education Trust Fund Grant Number TETF/DR&D/CE/NRF/CC/20/VOL 1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical approval for the conduct of the study was granted by the College Research Ethics Committee of the College of Health Sciences, Bayero University (Reference number: BUK/CHS-REC/121).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online via the link: https://data.mendeley.com/preview/hg7z83brcv?a=d8f53913-d5a9-4a49-8964-.
https://data.mendeley.com/preview/hg7z83brcv?a=d8f53913-d5a9-4a49-8964-
